Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · ICU Medical (ICUI)

ICU Medical Q4 revenue falls to $540.7 million; GAAP net loss narrows to $15.7 million

Negative Impact 3 of 5 earnings Written later

ICU Medical reported fourth quarter 2025 revenue of $540.7 million, down from $629.8 million a year earlier, and a GAAP net loss of $15.7 million, smaller than the prior-year loss of $23.8 million. Adjusted diluted EPS fell to $1.91 from $2.11, and adjusted EBITDA fell to $98.2 million from $105.5 million. The company also issued fiscal 2026 guidance of GAAP net income of $26 million to $44 million and adjusted EPS of $7.75 to $8.45.

Key points

  • Q4 2025 revenue was $540.7 million versus $629.8 million in Q4 2024; Vital Care fell $110.3 million after the IV Solutions business was disposed of on May 1, 2025
  • GAAP net loss was $(15.7) million, or $(0.64) per diluted share, versus $(23.8) million, or $(0.97), a year earlier
  • Adjusted diluted EPS was $1.91 versus $2.11; adjusted EBITDA was $98.2 million versus $105.5 million
  • Fiscal 2026 guidance: GAAP net income of $26 million to $44 million; adjusted EBITDA of $400 million to $430 million; adjusted EPS of $7.75 to $8.45

The filing

CompanyICU Medical (ICUI)
Form8-K, current report
Filed with the SECFeb 19, 2026, 4:08 PM ET
Accession number0000883984-26-000007

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:01 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 19, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.